Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Prognostic Model Developed for Major Outcomes in T1DM
Model has adequate discrimination; has been validated in three independent cohorts

FRIDAY, Aug. 29, 2014 (HealthDay News) -- A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online Aug. 28 in Diabetologia.

Sabita S. Soedamah-Muthu, Ph.D., from Wageningen University in the Netherlands, and colleagues developed a prognostic model and quantified its performance in independent cohorts. The authors analyzed data from 1,973 participants with type 1 diabetes from the EURODIAB Prospective Complications Study who were followed for seven years. Factors that were found to be prognostic for major outcomes were combined in a model, whose performance was tested in three prospective cohorts: the Pittsburgh Epidemiology of Diabetes Complications study (EDC; 554 participants); the Finnish Diabetic Nephropathy study (FinnDiane; 2,999 participants); and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI, 580 participants). Major coronary heart disease, stroke, end-stage renal failure, amputations, blindness, and all-cause death were included as major outcomes.

The researchers found that during follow-up, 95 patients from EURODIAB developed major outcomes. Hemoglobin A1c, waist-to-hip ratio, albumin/creatinine ratio, and high-density lipoprotein cholesterol level were identified as prognostic factors. The model had adequate discriminative ability, with a concordance statistic (C-statistic) of 0.74. Similar discrimination was seen in the validation cohorts, with C-statistics of 0.79, 0.82, and 0.73 for EDC, FinnDiane, and CACTI, respectively.

"Such a prognostic model may be helpful in clinical practice and for risk stratification in clinical trials," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)



Copyright © 2014 HealthDay. All rights reserved.

October 30, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Voters' Views on Affordable Care Act Split Along Party Lines

High Milk Intake Linked to Increased Mortality Risk

Less Competition Among Docs = Higher Medical Costs

Plastics' Chemical May Affect Boys' Genital Development

Depression Influences Post-Op Satisfaction in Older Patients

Clinical Illness, Outcomes for Ebola in Sierra Leone Reviewed